TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17132823
Drug: GH (2
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH (2 mg daily) + Acipimox (250 mg x 3 daily)
Study: 9536401
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract/carboxymethyl-beta-1,3-glucan formulation applied 2X a day for 2 weeks
Study: 2545773
Drug: Prior treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior treatment with pimozide
Study: 24342196
Drug: Iron protein
Normalized name: Iron Protein Succinylate
DrugBank: Iron protein succinylate (DB11209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron protein succinylate (IPS) oral solution
Study: 19494809
Drug: Fixed-dose MMF-treated
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose MMF-treated patients receiving tacrolimus with UGT1A9 -275T>A and/or -2152C>T polymorphism
Study: 16461866
Drug: CM and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM and 300 mg/d of bupropion hydrochloride (CMB)
Study: 15104569
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) with rFSH monotherapy
Study: 15354458
Drug: 0.42% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42% fluoride gel (8 applications at 3-month intervals)
Study: 3556337
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg orally
Study: 24599922
Drug: Biologics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics plus MTX
Study: 19342020
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard protocol for endometrial preparation)
Study: 14606933
Drug: Pimecrolimus (5-60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus (5-60mg single dose)
Study: 14606933
Drug: Pimecrolimus (5-30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus (5-30mg multiple doses)
Study: 1475622
Drug: Enteric-coated piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated piroxicam tablets (20 mg once daily for 2 weeks)
Study: 1475622
Drug: Plain piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plain piroxicam tablets (20 mg once daily for 2 weeks)
Study: 6383591
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy (intradermaIly with a Heaf gun and orally for 2 years)
Study: 20054045
Drug: Mupirocin nasal
Normalized name: mupirocin Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin nasal ointment and chlorhexidine soap
Study: 8548111
Drug: Parenteral antiarrhythmics
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antiarrhythmics
Study: 1785181
Drug: Live recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live recombinant influenza vaccine type A (H1N1)
Study: 1785181
Drug: Live recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live recombinant influenza vaccine type B
Study: 1785181
Drug: Mono-vaccine (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-vaccine (either A or B)
Study: 22148919
Drug: Achilles tendon
Normalized name: BOS TAURUS ACHILLES TENDON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achilles tendon vibration (1 h daily at 50 Hz for 14 days)
Study: 15109191
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation with midazolam (mean total dose 7.9 mg +/- 4.2 SD)
Study: 15109191
Drug: Operator-controlled sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operator-controlled sedation with midazolam (mean total dose 4.2 mg +/- 1.8 SD)
Study: 18276017
Drug: Pharmacotherapy (PT)
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (PT)
Study: 9925127
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation (8 mg elemental Fe, 5 mg elemental Zn, 333 microg retinol, 20 mg vitamin C 5 d/wk for 3 mo)
Study: 9925127
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation (20 mg Fe, 17 mg Zn, 1700 microg retinol, 20 mg vitamin C once a week for 3 mo)
Study: 2181223
Drug: ICRC anti-leprosy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICRC anti-leprosy vaccine
Study: 376132
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (procarbazine 100 mg/m2, Days 1‐‐10; vinblastine 5 mg/m2, Days 1 and 8; actinomycin D 0.5 mg/m2, Days 1 and 8)
Study: 376132
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with MER (200 micrograms in five sites)
Study: 376132
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with MER
Study: 31887853
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg preoperatively
Study: 31433708
Drug: Metacognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive therapy
Study: 26094723
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg t.d.s for 12 weeks, along with prednisolone 40 mg o.d. tapered over 12 weeks.
Study: 26094723
Drug: Clofazimine 100
Normalized name: clofazimine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 100 mg t.d.s for 12 weeks, along with prednisolone 40 mg o.d. tapered over 12 weeks.
Study: 22959555
Drug: 1-h infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h infusion of 0.5 g doripenem every 8 hours for seven doses
Study: 22959555
Drug: 4-h infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-h infusion of 0.5 g doripenem every 8 hours for seven doses
Study: 19079316
Drug: PCR-based preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCR-based preemptive therapy (group A)
Study: 19079316
Drug: Empirical antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antifungal therapy with liposomal amphotericin B (group B)
Study: 7745232
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon (GLU, 1 mg)
Study: 7745232
Drug: Intravenous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous glucagon (GLU, 1 mg)
Study: 7745232
Drug: Intravenous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous glucagon (GLU, 1 mg) with GHRH (1 microgram/kg)
Study: 7745232
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon (GLU, 1 mg) with GHRH (1 microgram/kg)
Study: 15361500
Drug: CDP571 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (10 mg/kg) in patients with baseline CRP >=10 mg/l
Study: 15361500
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in patients with baseline CRP >=10 mg/l
Study: 9844753
Drug: melatonin 5‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin 5‐mg fast‐release (FR) formulation
Study: 9844753
Drug: melatonin 0.5‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin 0.5‐mg fast‐release (FR) formulation
Study: 9844753
Drug: melatonin 2‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin 2‐mg controlled‐release (CR) formulation
Study: 7986000
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg, every 12 h, orally for 5 days)
Study: 7986000
Drug: Ceftriaxone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (3 g, once daily, intravenously for 3 days)
Study: 2658458
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg x 3
Study: 27572548
Drug: Dexmedetomidine 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg
Study: 23260750
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid emulsion (0.2 g/kg) over 6 h for 3 consecutive days
Study: 18496338
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (percutaneous radiofrequency neurotomy)
Study: 9164808
Drug: Moderate-mineral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-mineral formula (510 mg of calcium per liter and 390 mg of phosphorus per liter)
Study: 9164808
Drug: High-mineral formula
Normalized name: Mineral Oil (high Viscosity)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-mineral formula (1350 mg of calcium per liter and 900 mg of phosphorus per liter)
Study: 9164808
Drug: Cow milk
Normalized name: cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow milk (1230 mg of calcium per liter and 960 mg of phosphorus per liter)
Study: 3090860
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg DSCG rectally as enemas for eight weeks
Study: 20234364
Drug: CT+ZOL (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT+ZOL (neoadjuvant chemotherapy with zoledronic acid)
Study: 20234364
Drug: CT (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (neoadjuvant chemotherapy)
Study: 12655261
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg twice daily
Study: 11185667
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of 10 mg/m2
Study: 11185667
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of 30 mg/m2
Study: 11185667
Drug: s.c. bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. bolus of 20 mg/m2
Study: 11185667
Drug: s.c. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. administration
Study: 11185667
Drug: s.c. dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. dosing compared to i.v. dosing
Study: 11185667
Drug: Ribozyme administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ribozyme administration
Study: 1492863
Drug: Dihydroergocristine (DHEC)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (DHEC) 6 mg tablet daily for four months
Study: 2871007
Drug: Propranolol (PROP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (PROP, 160 mg/day)
Study: 2871007
Drug: Atenolol (ATEN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (ATEN, 100 mg/day)
Study: 9696964
Drug: Tiagabine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (4 mg three times daily for 9 days)
Study: 9696964
Drug: Digoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.5 mg twice a day for 1 day, then 0.25 mg once a day for 8 days)
Study: 9696964
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of tiagabine and digoxin
Study: 29361433
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text message intervention for 1 year
Study: 24723487
Drug: BEV/IRI (neo-adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEV/IRI (neo-adjuvant intravenous BEV, 10 mg/kg, and IRI, 125 mg/m², every 2 weeks for four cycles before RT; adjuvant BEV and IRI every 2 weeks for 6 months)
Study: 24723487
Drug: Control (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (concomitant oral TMZ, 75 mg/m²/day during RT, and 150-200 mg/m² for 5 days every 28 days for 6 months)
Study: 11378811
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (150 mg), alpha-tocopherol (75 mg), beta-carotene (15 mg), selenium (101 microg), and calcium (1.6 g)
Study: 9218294
Drug: Carmustine-loaded polymer
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine-loaded polymer (active treatment)
Study: 8356525
Drug: Control (existing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (existing therapy)
Study: 29688579
Drug: Avoralstat 500
Normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoralstat 500 mg
Study: 29688579
Drug: Avoralstat 300
Normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoralstat 300 mg
Study: 18633043
Drug: Pudendal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal nerve block with 15 mL of ropivacaine 7.5 mg/mL
Study: 17723130
Drug: Daily rFVIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rFVIIa prophylaxis with 90 microg kg(‐1) for 3 months
Study: 17723130
Drug: Daily rFVIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rFVIIa prophylaxis with 270 microg kg(‐1) for 3 months
Study: 17723130
Drug: Conventional on‐demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional on‐demand therapy
Study: 1571118
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate (900 mg) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Study: 1571118
Drug: Cefazolin sodium
Normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin sodium (2 g) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Study: 11273797
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid
Study: 29851070
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (0.02 g kg‐1 of an association of Lactobacillus acidophilus, Enterococcus faecium, Bifidobacterium thermophilum, and Bifidobacterium longum) with K2 Cr2 O7
Study: 29851070
Drug: K2 Cr2
Approvals — FDA: no, EMA: no, PMDA: no
Description: K2 Cr2 O7 at doses of 0.12 g kg‐1, 0.24 g kg‐1, and 0.36 g kg‐1
Study: 12206010
Drug: URA 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: URA 0.25 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U1)
Study: 12206010
Drug: URA 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: URA 0.5 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U2)
Study: 29630033
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block (ISB) with 20 mL of levobupivacaine 0.5% and epinephrine 5 μg/mL
Study: 29630033
Drug: Small-volume supraclavicular
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-volume supraclavicular block (SCB) with 20 mL of levobupivacaine 0.5%
Study: 27064369
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) using the novel negative pressure device (NPD)
Study: 24216257
Drug: Oral Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Supplementation (OS)
Study: 16054520
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5, 5 x 10(7) cfu/tablet)
Study: 11199957
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release 300 mg/day
Study: 9531003
Drug: Prescribed intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed intake of carbohydrate-electrolyte solution (6.9% Lucozade-Sport; sodium, 24 mmol l(‐1); potassium, 2.6 mmol l(‐1); calcium, 1.2 mmol l(‐1); osmolality, 300 mOsm kg(‐1))
Study: 9531003
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum intake of carbohydrate-electrolyte solution
Study: 9531003
Drug: Prescribed intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed intake of carbohydrate-electrolyte solution
Study: 8270977
Drug: L-PAM plus
Normalized name: L-PAM
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-PAM plus BSO
Study: 8270977
Drug: L-PAM alone
Normalized name: L-PAM
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-PAM alone
Study: 25492378
Drug: Sensor-augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented therapy
Study: 21255828
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (1 mg/kg infusion on alternate days for 30 days, total dose 15 mg/kg)
Study: 21255828
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B with miltefosine (single injection of 5 mg/kg liposomal amphotericin B and 7-day 50 mg oral miltefosine)
Study: 21255828
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B with paromomycin (single 10-day 11 mg/kg intramuscular paromomycin)
Study: 21440702
Drug: Constraint‐Induced Movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐Induced Movement Therapy (CIMT)
Study: 10681486
Drug: triflusal 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: triflusal 600 mg once daily for 35 days
Study: 10681486
Drug: aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 300 mg once daily for 35 days
Study: 9018764
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide (4 mg twice daily for 1 week)
Study: 29482543
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (NSPT) with immediate ultrasonic scaling, scaling and root planning, and subgingival 10% povidone iodine irrigation.
Study: 20046552
Drug: Manual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual treatment technique (4-minute pain-alleviating traction) at the most symptomatic zygopophyseal joint
Study: 20046552
Drug: Manual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual treatment technique (4-minute pain-alleviating traction) 3 segments away from the concordant segment
Study: 15102867
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg bid IV for 6 days with UFH on day 5 (n = 18)
Study: 15102867
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) alone (n = 18)
Study: 12122123
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for Charcot's arthropathy; specific intervention details not provided.
Study: 7783654
Drug: Vasodilator administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasodilator administration (prazosin and hydralazine) alone or in combination with a beta‐blocker (propranolol)
Study: 7783654
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (vasodilators + propranolol)
Study: 2295294
Drug: Loxiglumide (CCK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK antagonist), 800 mg (two tablets of 400 mg each)
Study: 381006
Drug: (‐)eburnamonine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: (‐)eburnamonine (80 mg/day for the first 5 days, then 60 mg/day for at least 20 days)
Study: 381006
Drug: Nicergoline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (20 mg/day for the first 5 days, then 15 mg/day for at least 20 days)
Study: 7013976
Drug: Doxorubicin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (300 mg/kg)
Study: 7013976
Drug: Cycloleucine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloleucine (300 mg/kg)
Study: 7013976
Drug: Cycloleucine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloleucine (200 mg/kg)
Study: 28762160
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for children with ASD
Study: 28762160
Drug: All parents
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All parents (including treatment and control)
Study: 26106962
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination formulation
Study: 22695489
Drug: Almorexant (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almorexant (evening administration)
Study: 17526469
Drug: Olanzapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-20 mg/d) with diet modifications (500 kcal/d less than usual) and moderate physical activity (jogging lightly for 30 min 3 times a week)
Study: 17526469
Drug: Olanzapine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-20 mg/d) only
Study: 15583924
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with HELBO Blue and TheraLite laser
Study: 12297170
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) KIU loading dose and 0.5 x 10(6) KIU/h during surgery, n=22)
Study: 12297170
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control, n=25)